Explore the sources behind the guidance, including study limitations and provenance.
The ibogaine medical subcultureAlper · 2008 · Peer Reviewed · Other
Ibogaine in acute opioid withdrawal: An open label case seriesAlper · 2000 · Peer Reviewed · Case Report
Fatalities temporally associated with the ingestion of ibogaineAlper · 2012 · Peer Reviewed · Case Report
hERG blockade by iboga alkaloidsAlper · 2016 · Peer Reviewed · Mechanistic Study
The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused updateAmerican Society of Addiction Medicine. · 2020 · Specialty Authority · Specialty Standard
Ibogaine and subjective experience: Transformative states and psychopharmacotherapy in the treatment of opioid use disorderBrown · 2019 · Peer Reviewed · Primary Human Study
Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmiasBrunt · 2026 · Peer Reviewed · Primary Human Study
Psychedelic-related psychosis: From model psychosis to psychotherapyBröcker · 2026 · Peer Reviewed · Primary Human Study
Traumatic psychedelic experiencesCalder · 2026 · Peer Reviewed · Primary Human Study
Magnesium–ibogaine therapy in veterans with traumatic brain injuriesCherian · 2024 · Peer Reviewed · Primary Human Study
Transpersonal intersubjectivity in ibogaine experiences: Three casesDickinson · 2023 · Peer Reviewed · Primary Human Study
Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology FoundationDrew · 2010 · Specialty Authority · Specialty Standard
A case series of ibogaine toxicity reported to the United Kingdom National Poisons Information Service (NPIS) over a 10 year periodEdwards · 2025 · Peer Reviewed · Case Report
Ibogaine: Therapeutic potential, cardiac safety, and translational perspectives in the treatment of substance use disorders—A scoping reviewEsperança · 2026 · Peer Reviewed · Systematic Review
Unpeeling the evidence for the banana bag: Evidence-based recommendations for the management of alcohol-associated vitamin and electrolyte deficiencies in the ICUAlexander H. Flannery, David A. Adkins, Aaron M. Cook · 2016 · Peer Reviewed · Other
Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patientsGlue · 2016 · Peer Reviewed · Primary Human Study
Ascending dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerabilityGlue · 2015 · Peer Reviewed · Primary Human Study
Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteersGlue · 2015 · Peer Reviewed · Primary Human Study
The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine’s subjective effectsGonzález Espejito · 2025 · Peer Reviewed · Primary Human Study
Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: A study of sotalol effects on T-wave morphologyGraff · 2009 · Peer Reviewed · Primary Human Study
Examination of the phenomenology of the ibogaine treatment experience: Role of altered states of consciousness and psychedelic experiencesHeink · 2017 · Peer Reviewed · Primary Human Study
Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaineHenstra · 2017 · Peer Reviewed · Case Report
A case of QT prolongation and torsades de pointes caused by ibogaine toxicityHildyard · 2016 · Peer Reviewed · Case Report
Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: A case control pilot studyHinterseer · 2008 · Peer Reviewed · Primary Human Study
Ibogaine associated psychosis in schizophrenia: A case reportHouenou · 2011 · Peer Reviewed · Case Report
Disrupting substance use disorder: The chemistry of iboga alkaloidsHughes · 2024 · Peer Reviewed · Primary Human Study
Thirty years of ibogaine research: A literature review on clinical perspectivesKervadec · 2026 · Peer Reviewed · Systematic Review
Safety of ibogaine administration in detoxification of opioid dependent individuals: A descriptive open label observational studyKnuijver · 2022 · Peer Reviewed · Primary Human Study
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patientsKnuijver · 2024 · Peer Reviewed · Primary Human Study
The ibogaine experience: A qualitative study on the acute subjective effects of ibogaineKohek · 2020 · Peer Reviewed · Primary Human Study
Liquid chromatography electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood: Application to a poisoning involving Tabernanthe iboga rootKontrimavičiūtė · 2006 · Peer Reviewed · Primary Human Study
Evaluation of the QT interval in patients with drug-induced QT prolongation and torsades de pointesKrisai · 2020 · Peer Reviewed · Primary Human Study
A systematic literature review of clinical trials and therapeutic applications of ibogaineKöck · 2022 · Peer Reviewed · Systematic Review
Ginger for treating nausea and vomiting: An overview of systematic reviews and meta-analysesLi · 2024 · Peer Reviewed · Systematic Review
How toxic is ibogaine?Litjens · 2016 · Peer Reviewed · Primary Human Study
Observations on treatment with ibogaineLuciano · 1998 · Peer Reviewed · Primary Human Study
A comparison of commonly used QT correction formulae: The effect of heart rate on the QTc of normal ECGsLuo · 2004 · Peer Reviewed · Primary Human Study
Reply to Knuijver et al. on the “Safety of ibogaine administration in detoxification of opioid-dependent individuals: A descriptive open-label observational study.”Luz · 2022 · Peer Reviewed · Primary Human Study
Randomised trial of intravenous thiamine and/or magnesium sulphate administration on erythrocyte transketolase activity, lactate concentrations and alcohol withdrawal scoresMaguire · 2022 · Peer Reviewed · Primary Human Study
Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaineMalcolm · 2018 · Peer Reviewed · Primary Human Study
Mania following use of ibogaine: A case seriesMarta · 2015 · Peer Reviewed · Case Report
IUPHAR invited review: Ibogaine—A legacy within the current renaissance of psychedelic therapyMash · 2023 · Peer Reviewed · Systematic Review
Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measuresMash · 2000 · Peer Reviewed · Primary Human Study
Fatal case of a 27 year old male after taking iboga in withdrawal treatment: GC MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological materialMazoyer · 2013 · Peer Reviewed · Primary Human Study
Multiple episodes of cardiac arrest induced by treatment with ibogaine: A case reportMestre · 2024 · Peer Reviewed · Case Report
Ibogaine/noribogaine in the treatment of substance use disorders: A systematic review of the current literatureMosca · 2023 · Peer Reviewed · Systematic Review
Ibogan, aspidosperman, vincamine, and bisindole alkaloids from a Malayan Tabernaemontana corymbosa: Iboga alkaloids with C 20α substitutionNge · 2016 · Peer Reviewed · Primary Human Study
The adverse events of ibogaine in humans: An updated systematic review of the literature (2015–2020)Ona · 2022 · Peer Reviewed · Systematic Review
Internet purchased ibogaine toxicity confirmed with serum, urine, and product content levelsO’Connell · 2015 · Peer Reviewed · Case Report
The PRISMA 2020 statement: An updated guideline for reporting systematic reviewsPage · 2021 · Peer Reviewed · Systematic Review
A framework for assessment of adverse events occurring in psychedelic assisted therapiesPalitsky · 2024 · Peer Reviewed · Primary Human Study
Ibogaine related sudden death: A case reportPapadodima · 2013 · Peer Reviewed · Case Report
Developing guidelines and competencies for the training of psychedelic therapistsPhelps · 2017 · Specialty Authority · Specialty Standard
Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: A pilot, open-label studyRocha · 2026 · Peer Reviewed · Primary Human Study
Identifying setting factors associated with improved ibogaine safety: A systematic review of clinical studiesRocha · 2023 · Peer Reviewed · Systematic Review
Guidelines for establishing safety in ayahuasca and ibogaine administration in clinical settingsRocha · 2023 · Specialty Authority · Specialty Standard
Studies on the iboga cults. IV. The ethnobotanical complexSamorini · 2025 · Traditional Community · Traditional Ethnographic
A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatmentSchenberg · 2017 · Peer Reviewed · Primary Human Study
Ibogaine for treating drug dependence: What is a safe dose?Schep · 2016 · Peer Reviewed · Primary Human Study
From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disordersSharma · 2026 · Peer Reviewed · Systematic Review
Mortality risk during and after opioid substitution treatment: Systematic review and meta analysis of cohort studiesSordo · 2017 · Peer Reviewed · Systematic Review
Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up studyStrang · 2003 · Peer Reviewed · Primary Human Study
Psychedelics and the thalamocortical system: A scoping reviewVillalba · 2026 · Peer Reviewed · Systematic Review
Part 9: Advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular careWigginton · 2025 · Specialty Authority · Specialty Standard
Integration of vestibular and emetic gastrointestinal signals that produce nausea and vomiting: Potential contributions to motion sicknessYates · 2014 · Peer Reviewed · Mechanistic Study
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathZeppenfeld · 2022 · Specialty Authority · Specialty Standard
Clinical Guidelines for Ibogaine-Assisted Detoxification (Version 1.1). Global Ibogaine Therapy AllianceDickinson · 2016 · Community · Community Guidance
Manual for Ibogaine Therapy: Screening, Safety, Monitoring & Aftercare (2nd rev.). Ibogaine DossierLotsof · 2003 · Community · Community Guidance
Notes for Ibogaine Treatment Providers [field notes based on 2001–2002 provider experience]. Ibogaine DossierWells · Undated · Named Provider Program · Provider Commentary
Ibogaine Patient’s Bill of Rights. Reproduced in Clinical Guidelines for Ibogaine-Assisted Detoxification (GITA, Version 1.1)Ibogaine Patient’s Bill of Rights. Reproduced in Clinical Guidelines for Ibogaine-Assisted Detoxification (GITA · Undated · Community · Community Guidance
A qualitative inquiry into practitioners’ experiences of using ibogaine and other psychoplastogens in the treatment of substance misuse [Doctoral thesis, Lancaster University]Enginsoy · 2025 · Community · Provider Commentary
Minimal standards of care in ibogaine therapy [Conference presentation, Barcelona]Global Ibogaine Therapy Alliance. · 2010 · Community · Community Guidance
Ethical considerations in ibogaine therapy [Conference presentation, 2nd International Ibogaine Therapy Provider Conference, Barcelona]Karpetas · 2010 · Community · Community Guidance
Ibogaine: Information and guidelines for integrated therapyI.ACT Aotearoa/New Zealand. · 2014 · Community · Community Guidance
Ibogaine in the 21st century: Boosters, tune-ups and maintenance. MAPS Bulletin, 15(1), 21–24Kroupa · 2005 · Named Provider Program · Provider Commentary
Cumulative dosing [Named contemporary provider practice page]Pangea Biomedics. · 2026 · Named Provider Program · Provider Commentary
Program overview [Named contemporary provider program description]The Mission Within. · 2026 · Named Provider Program · Provider Commentary
Hattie Wells on ibogaine treatment [Podcast interview]. Psychoactive. iHeartWells · 2022 · Named Provider Program · Provider Commentary
Preparation & Integration WorkbookSacred Warrior Community. · Undated · Named Provider Program · Participant Report
How does psychedelic treatment work for PTSD? [Podcast interview and transcript]. Modern Wisdom, Episode 494Polanco · 2022 · Named Provider Program · Provider Commentary
Dr. Ramirez: Going deep while staying safe [Named contemporary program operations article]Beond Ibogaine. · Undated · Named Provider Program · Provider Commentary
Hilda Sánchez: Is ibogaine safe? [Podcast interview]. Ibogaine Uncovered, Episode 63Beond Ibogaine. · 2026 · Named Provider Program · Provider Commentary
A day in the life of an onsite Preparation & Integration Coach at Beond [Official LinkedIn post]Beond Ibogaine. · Undated · Named Provider Program · Provider Commentary
Patient safety, transparency, and revisions to detox protocols [Program quality-improvement disclosure]Ambio Life Sciences. · 2026 · Named Provider Program · Provider Commentary
FAQs [Current program description; includes program-specific “Gray Day” usage]Ambio Life Sciences. · 2026 · Named Provider Program · Provider Commentary
Ibogaine and traumatic brain injury: A new treatment frontier [Podcast interview]. The Psychedelic Podcast, Episode 347, Third WaveDickinson · 2026 · Named Provider Program · Provider Commentary
How ibogaine triggers neuroplasticity and lasting change [Official LinkedIn post featuring Trevor Millar’s integration commentary]Ambio Life Sciences. · 2026 · Named Provider Program · Provider Commentary
Psychedelic preparation [Unpublished presentation notes]Nicolas · 2023 · Project · Project source
Ibogaine investigator’s brochure (Version 1, June 1, 2026). Secondary compendium used for source discovery and cross checking; the brochure states that it is not intended to guide clinical careMultidisciplinary Association for Psychedelic Studies. · 2026 · Project · Project source
Project template supplied for the Global Competencies in Psychedelic FacilitationIbogaine Safety and Risk Management Applied Lens Template. · 2026 · Project · Project source
Cardiac morphology during drug-induced QT prolongation: An educational review [Unpublished preprint]Nicolas · 2026 · Project · Project source
Banana and excessive visions: word of mouth from indigenous practiceWord of mouth from indigenous iboga practice: banana is offered with the intention of reducing visions when they become too intense. · Undated · Project · Project source
Defining a Healthy Diet: Evidence for the Role of Contemporary Dietary Patterns in Health and DiseaseHellas Cena, Philip C. Calder · 2020 · Peer Reviewed · Other
Human hallucinogen research: Guidelines for safetyMatthew W. Johnson, William A. Richards, Roland R. Griffiths · 2008 · Peer Reviewed · Other
Contextual care and communication revisionContextual care and communication revision (22 September 2026). Project editorial synthesis prepared for private review. · 2026 · Project · Project source
Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment OutcomesDeborah C. Mash, Linda Duque, Bryan Page, Kathleen Allen-Ferdinand · 2018 · Peer Reviewed · Primary Human Study
Jeff McNairy on banana use during iboga experiences [practitioner interview, 38:51]Jeff McNairy, Nick Urban · 2026 · Named Provider Program · Provider Commentary
Pharmacological treatment of acquired QT prolongation and torsades de pointesSimon H. L. Thomas, Elijah R. Behr · 2016 · Peer Reviewed · Other
Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy SocietyEvidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. · 2016 · Specialty Authority · Specialty Standard
Treatment of drug-induced seizuresHsien-Yi Chen, Timothy E. Albertson, Kent R. Olson · 2016 · Peer Reviewed · Other
Randomized Trial of Three Anticonvulsant Medications for Status EpilepticusRandomized Trial of Three Anticonvulsant Medications for Status Epilepticus. · 2019 · Peer Reviewed · Primary Human Study
PONV management in patients with QTc prolongation on the EKGS. Soghomonyan, N. Stoicea, W. Ackermann, S. P. Bhandary · 2021 · Peer Reviewed · Other
Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteersEffect of single doses of IV palonosetron · 2016 · Peer Reviewed · Primary Human Study
Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjectsLack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. · 2009 · Peer Reviewed · Primary Human Study
Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetronBeny Charbit, Pierre Albaladejo, Christian Funck-Brentano, Mathieu Legrand, Emmanuel Samain, Jean Marty · 2005 · Peer Reviewed · Primary Human Study
Management of serotonin syndrome (toxicity)Angela L. Chiew, Geoffrey K. Isbister · 2025 · Peer Reviewed · Other
Can 5-HT3 Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and OrderCarlos H. Rojas-Fernandez · 2014 · Peer Reviewed · Other
The ASAM Clinical Practice Guideline on Alcohol Withdrawal ManagementThe ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. · 2020 · Specialty Authority · Specialty Standard
